Angela Johnson
Family · Winfield, KSNPI 1770129140
Payments from drug & device makers
Across 89 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$364
- Novo Nordisk$305
- Amgen$149
- Lilly USA, LLC$146
- Sanofi-aventis U.S. LLC$100
- Insulet Corporation$67
- plus $411 from 17 others
What the payments were for
- Food & beverage$1,541100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $364 |
| Novo Nordisk | 17 | $305 |
| Amgen | 8 | $149 |
| Lilly USA, LLC | 10 | $146 |
| Sanofi-aventis U.S. LLC | 6 | $100 |
| Insulet Corporation | 3 | $67 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $50 |
| GSK | 3 | $48 |
| Lundbeck LLC | 2 | $45 |
| Pfizer | 3 | $42 |
| Bayer | 2 | $34 |
| Sanofi Pasteur Inc. | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Medtronic | 1 | $15 |
| Abbott | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Merck | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| AbbVie | 1 | $13 |
| Mylan Specialty L.p. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$1,541 in reported general payments places this provider in the 80th percentile of 1,579 family providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 48 | $46,719 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $22,158 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 14 | $16,111 |
| JardianceEmpagliflozin | 15 | $10,788 |
| XareltoRivaroxaban | 14 | $10,687 |
| FarxigaDapagliflozin Propanediol | 12 | $8,986 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $5,947 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $5,557 |
| Aripiprazole | 20 | $5,305 |
| Novolog FlexpenInsulin Aspart | 26 | $4,532 |
| Esomeprazole Magnesium | 13 | $1,367 |
| Losartan Potassium | 116 | $1,107 |
| Gabapentin | 99 | $1,006 |
| Levothyroxine Sodium | 128 | $985 |
| Atorvastatin Calcium | 147 | $876 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6 | $305 | $62,83062 claims |
| Boehringer IngelheimJardiance | $19 | $10,78815 claims |
| Johnson & JohnsonXarelto | $14 | $10,68714 claims |
| AstraZenecaFarxiga | $364 | $8,98612 claims |
| GSKBreo Ellipta | $48 | $5,55714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,579 family providers in Kansas.
Other family in Winfield
- Zohra HussainiKansas City$329K
- Jennifer ChesterOverland Park$327K
- Amanda CaldwellLeawood$203K
- Kayla del RioWichita$147K
- Kelli RiceWichita$114K
- Tatum TolandTopeka$108K
- Mary GonzalesWichita$87K
- Erin FeitzOverland Park$36K
- Adam CaseKansas City$34K
- Jaimie HeldstabWestwood$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.